-
Subject Areas on Research
-
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
-
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
-
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
-
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
-
Dietary and commercialized fructose: Sweet or sour?
-
Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target?
-
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
-
Febuxostat: a new agent for lowering serum urate.
-
Genetics of hyperuricemia and gout: implications for the present and future.
-
Gout and its comorbidities.
-
Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.
-
Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?
-
Hyperuricemia, gout, and cardiovascular disease--an important "muddle".
-
Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
-
Normal glycine-C14-incorporation into uric acid in primary gout.
-
On the mechanism of overproduction of uric acid in patients with primary gout.
-
Overproduction of uric acid as the cause of hyperuricemia in primary gout.
-
Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients.
-
Progress in the pharmacotherapy of gout.
-
Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
-
Safety of urate-lowering therapies: managing the risks to gain the benefits.
-
Serum uric acid and hyperuricemia in U.S. adolescents: 40-year trends.
-
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
-
Update on the management of hyperuricemia and gout.
-
Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure.
-
Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.
-
Keywords of People